TYRA Logo

Tyra Biosciences, Inc. (TYRA) 

NASDAQ
Market Cap
$898.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
214 of 776
Rank in Industry
124 of 433

Largest Insider Buys in Sector

TYRA Stock Price History Chart

TYRA Stock Performance

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company …

Insider Activity of Tyra Biosciences, Inc.

Over the last 12 months, insiders at Tyra Biosciences, Inc. have bought $151,954 and sold $10.04M worth of Tyra Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Tyra Biosciences, Inc. have bought $24.48M and sold $11.26M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Fuhrman Alan (Chief Financial Officer) — $151,954.

The last purchase of 9,500 shares for transaction amount of $151,954 was made by Fuhrman Alan (Chief Financial Officer) on 2024‑10‑30.

List of Insider Buy and Sell Transactions, Tyra Biosciences, Inc.

2024-11-01Saledirector
27,493
0.0527%
$16.56$455,272+0.18%
2024-10-31Saledirector
100,140
0.1874%
$16.46$1.65M-1.65%
2024-10-30Saledirector
11,078
0.0213%
$16.17$179,120+2.82%
2024-10-30PurchaseChief Financial Officer
9,500
0.018%
$16.00$151,954+2.82%
2024-10-21SalePresident and CEO
19,084
0.0356%
$27.90$532,451-42.12%
2024-10-18SalePresident and CEO
43,636
0.0818%
$27.01$1.18M-39.44%
2024-10-17SalePresident and CEO
15,394
0.029%
$25.85$397,872-35.80%
2024-10-16SalePresident and CEO
33,297
0.0706%
$26.17$871,430-35.15%
2024-10-15SalePresident and CEO
10,035
0.0198%
$24.31$243,970-30.87%
2024-09-30SalePresident and CEO
500
0.001%
$24.00$12,000-7.32%
2024-09-25SalePresident and CEO
600
0.0012%
$24.01$14,406-2.54%
2024-09-24SalePresident and CEO
1,055
0.002%
$24.02$25,341-2.58%
2024-09-23SalePresident and CEO
10,092
0.0195%
$24.13$243,477-7.02%
2024-09-20SalePresident and CEO
7,109
0.0134%
$24.19$171,950-9.61%
2024-09-19SalePresident and CEO
5,698
0.0109%
$24.31$138,491-8.17%
2024-09-18SalePresident and CEO
3,500
0.0069%
$24.00$84,000-5.00%
2024-06-10SaleChief Operating Officer
3,502
0.0067%
$20.00$70,045+6.20%
2024-06-07SaleChief Operating Officer
200
0.0004%
$20.00$4,000+7.03%
2024-03-11SaleChief Operating Officer
200
0.0005%
$20.00$4,000-3.75%
2024-03-07SaleChief Operating Officer
68
0.0002%
$20.00$1,360-3.36%

Insider Historical Profitability

<0.0001%
Fuhrman AlanChief Financial Officer
12849
0.0244%
$17.0310
Boxer Capital, LLC10 percent owner
6448359
12.2275%
$17.0320<0.0001%
RA CAPITAL MANAGEMENT, L.P.
5297120
10.0445%
$17.0310<0.0001%
MORE ROBERT Jdirector
4080296
7.7371%
$17.0310<0.0001%
Alta Partners NextGen Fund II Management, LLC10 percent owner
4080296
7.7371%
$17.0310<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$170.83M19.8310.42M+43.95%+$52.15M0.17
Boxer Capital, LLC$105.75M12.276.45M0%+$02.17
Bvf Inc Il$76.44M8.874.66M+70.14%+$31.51M0.56
Canaan Partners Xi Llc$72.32M8.394.41M0%+$079.77
Nextech Invest$66.52M7.724.06M+61.04%+$25.21M10.85
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.